EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Temporal Effect on PD ‐ L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer

Gopal P Pathak, Rashmi Shah, Mathieu Castonguay, Angela Cheng iD, John Fris, Rowan Murphy, Gail Darling, Alexander Ednie, Daniel French, Harry Henteleff, Aneil Mujoomdar, Madelaine Plourde und 2 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.70262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Gopal P Pathak und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, QEII Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, B7-H1 Antigen, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Atlantic Cancer Consortium (ACC), Dalhousie University, Nova Scotia Health Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Several studies rely on archived tissue blocks to assess the PD‐L1 scores; however, a detailed analysis of potential variations of scores between fresh and archived tissue blocks still lacks. In addition, the prognostic implications of PD‐L1 in lung cancers have not yet been completely understood. Here, we aimed to investigate the temporal variation in PD‐L1 scores from clinical samples and the clinical implications of PD‐L1 in non–small cell lung cancer (NSCLC).

Methods

NSCLC cases from January 2005 to June 2023 were considered for this study, and PD‐L1 scores in archived and fresh tissue blocks were analyzed. Association of PD‐L1 with various driver mutations was explored, and implications of PD‐L1 in progression‐free survival (PFS) and overall survival (OS) were analyzed.

Results

Our study revealed a significant disparity in PD‐L1 scores between archived and fresh tissue blocks, and a temporal variation in scores within 6 months of tissue acquisition. Advanced‐stage primary tumors, metastatic lymph nodes, and visceral pleural invasion revealed higher PD‐L1 expression as presented by tumor proportion score (TPS). Notably, in fully resected stage I/II NSCLC cases, OS was better in the high PD‐L1 (≥ 50% TPS) cohort with driver mutations compared to cases without driver mutations (hazard ratio—0.5129, 95% confidence interval 0.2058–1.084, p = 0.0779). In contrast, high PD‐L1 was associated with worse OS compared to no PD‐L1 (< 1% TPS) (hazard ratio—2.431, 95% confidence interval 1.144–6.656, p = 0.0242) in the cohort without driver mutations. Furthermore, the presence of a KRAS mutation favored the outcome of anti‐PD‐L1/PD1 immunotherapy in advanced NSCLC.

Conclusion

PD‐L1 detection from tissue blocks was found to vary temporally, urging for a prioritized consideration for patients with marginal scores when archived blocks are employed for its detection. Prognostic roles of PD‐L1 were associated with driver mutations, and KRAS mutations favored the outcome of anti‐PD‐L1/PD1 therapy in advanced NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungB7-H1 AntigenLung NeoplasmsHumansMaleFemaleMiddle AgedAgedPrognosisBiomarkers, TumorMutationNeoplasm StagingRetrospective StudiesProgression-Free SurvivalTime Factors

Stichwörter der Autor:innen

NSCLCPD‐L1checkpoint inhibitordriver mutationimmunotherapy

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, QEII Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
  • Division of Thoracic Surgery, QEII Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.

ORCID-Profile: Angela Cheng, Zhaolin Xu

Förderung

  • Atlantic Cancer Consortium (ACC)
  • Dalhousie University
  • Nova Scotia Health Authority
  • Merck Canada

Zitieren

APA

Pathak, G. P., Shah, R., Castonguay, M., Cheng, A., Fris, J., Murphy, R., Darling, G., Ednie, A., French, D., Henteleff, H., Mujoomdar, A., Plourde, M., Wallace, A., & Xu, Z. (2024). Temporal Effect on PD ‐ L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70262

Vancouver

Pathak GP, Shah R, Castonguay M, Cheng A, Fris J, Murphy R, et al. Temporal Effect on PD ‐ L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer. Cancer Medicine. 2024. doi:10.1002/cam4.70262

BibTeX
@article{Pathak2024,
  author = {Pathak, Gopal P and Shah, Rashmi and Castonguay, Mathieu and Cheng, Angela and Fris, John and Murphy, Rowan and Darling, Gail and Ednie, Alexander and French, Daniel and Henteleff, Harry and Mujoomdar, Aneil and Plourde, Madelaine and Wallace, Alison and Xu, Zhaolin},
  title = {Temporal Effect on PD ‐ L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70262}
}
Kostenlos starten →